+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 12 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating the safety and effects of a new drug called NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction HFpEF or Heart Failure with mildly reduced Ejection Fraction HFmrEF who also have excess body weight. This study compares NNC0487-0111 against a placebo to determine if it is safe and effective for treating these heart conditions in people with obesity. The study is a randomized, controlled trial conducted by Novo Nordisk AS. Participants will receive either NNC0487-0111 or a placebo by subcutaneous injection once a week. The study drug dose may increase over time for those receiving NNC0487-0111. Treatment assignment is random, and the study includes a parallel design with two groups one receiving the experimental drug and one receiving placebo. The treatment period and monitoring last up to 165 weeks. During the study, participants will be monitored for heart failure events, cardiovascular death, hospital visits related to heart failure, and other major cardiovascular outcomes. They will complete questionnaires about their heart failure symptoms and quality of life. Kidney function will also be assessed in some participants. Safety and effectiveness will be evaluated throughout the study period, which can last over three years, with regular visits for injections and assessments.

Age: 18Years +All GendersPhase 3
838 locations
E

Actively Recruiting

Researchers are evaluating the effects of different dosing schedules of LAD191 in adults with moderate-to-severe Hidradenitis Suppurativa HS. This phase 2 study aims to compare LAD191 with a placebo and adalimumab, focusing on how well the treatments work, their safety, tolerability, how the body processes the drug, and immune system responses. The study uses an adaptive design with interim data to assess whether to continue certain doses. Participants will undergo up to 4 weeks of screening before entering a 16-week double-blind, placebo-controlled treatment period Treatment Period 1. Then, all participants will receive LAD191 in a 16-week double-blind period Treatment Period 2. The study includes five groups three doses of LAD191, placebo during the first period then LAD191, or adalimumab during the first period then LAD191. After these treatment periods, there is a 12-week safety follow-up. During the study, participants will receive subcutaneous injections as per their assigned group. Researchers will assess the proportion of participants achieving significant reductions in HS lesions at week 16 using clinical response scores. Additional measures include skin pain levels and quality of life related to HS. Safety, tolerability, and other health evaluations will occur throughout the trial. Total participation spans screening, two treatment periods, and safety monitoring until study completion.

Age: 18Years - 65YearsAll GendersPhase 2
1 location
E

Actively Recruiting

Researchers are evaluating the combined use of finerenone and empagliflozin compared to usual care to assess their safety and effectiveness in patients hospitalized with heart failure. This international, randomized, controlled, open-label trial aims to study an early, intensive management approach for heart failure treatment. Participants will be assigned to receive either the combination of oral finerenone plus oral empagliflozin or usual care. The study focuses on treatment during hospitalization and shortly after, comparing these approaches to understand the clinical benefits and risks over a six-month period. During the trial, participants will be monitored for clinical outcomes including serious adverse events and events leading to treatment discontinuation. Researchers will measure heart failure events, symptom changes using the Kansas City Cardiomyopathy Questionnaire, and overall survival up to six months. Safety and efficacy data will be collected throughout the study period ending in November 2027.

Age: 18Years +All GendersPhase 3
140 locations
R

Actively Recruiting

Researchers are evaluating the effectiveness and safety of finerenone compared to a placebo in patients hospitalized with acute decompensated heart failure who have mildly reduced or preserved left ventricular ejection fraction. This international, randomized, double-blind, placebo-controlled Phase 3 trial aims to study how finerenone affects morbidity and mortality in these patients. Participants will be randomly assigned to receive either oral finerenone or a matching placebo. The study is event-driven and will monitor patients for up to approximately 30 months. It includes ongoing evaluation of heart failure events, cardiovascular death, and adverse events related to the study drug. Both groups will be observed throughout this period to compare outcomes. During the trial, participants will undergo regular assessments including monitoring for heart failure events, cardiovascular death, and serious adverse events. The study will also measure changes in symptom scores using the Kansas City Cardiomyopathy Questionnaire at 6 months. Safety and tolerability will be closely tracked, including adverse events leading to discontinuation of the study drug. Participants will be followed for up to 30 months to assess long-term effects.

Age: 18Years +All GendersPhase 3
356 locations
S

Actively Recruiting

Researchers are evaluating finerenone compared to a placebo to assess the effectiveness and safety of treatment in patients with heart failure and reduced ejection fraction HFrEF who cannot tolerate or are not eligible for steroidal mineralocorticoid receptor antagonists sMRA. This international study is a randomized, double-blind, placebo-controlled trial focused on this specific group of heart failure patients. Participants will be randomly assigned to receive either oral finerenone or a matching placebo. The study uses a parallel design and treatment will be monitored for up to about 30 months. During this time, researchers will track cardiovascular events, heart failure events, and any serious or adverse events leading to discontinuation of the study drug. Throughout the study, participants will undergo regular assessments including symptom questionnaires and monitoring for cardiovascular outcomes and safety. The main outcomes include the time to the first cardiovascular death or heart failure event and the number of serious adverse events. The study also tracks changes in symptom scores over six months and overall survival. Participants will be followed closely during treatment and after to understand both efficacy and safety.

Age: 18Years +All GendersPhase 3
176 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of bimekizumab compared to a placebo in adults with palmoplantar pustulosis PPP, a condition characterized by pustules on the palms and soles. This Phase 3 study aims to provide important information about this treatment option in participants who have had PPP for at least 24 weeks and meet specific severity criteria. Participants will be randomly assigned to one of two groups one receiving bimekizumab throughout the study and the other receiving a placebo initially, then switching to bimekizumab during the maintenance phase. The treatments are given at scheduled times, and the study includes an open-label extension period to further assess the treatment. During the study, participants will have regular assessments of their skin condition, including the Palmoplantar Pustulosis-Investigator Global Assessment and Palmoplantar Pustulosis Area Severity Index at weeks 8 and 16. Quality of life and pain levels will also be evaluated. Safety is closely monitored through the recording of any adverse events up to approximately 117 weeks. The total time commitment includes initial treatment and an extended safety follow-up period.

Age: 18Years +All GendersPhase 3
91 locations
R

Actively Recruiting

Researchers are evaluating brivekimig in a Phase 2b study for people with moderate to severe hidradenitis suppurativa HS, a chronic skin condition. The study is designed to test the safety and effectiveness of different doses of brivekimig compared to a placebo. This global, multicenter trial uses a randomized, double-blind, placebo-controlled, parallel group design to ensure reliable results. Participants receive one of three brivekimig dose regimens or a matching placebo through subcutaneous injections. The main studys randomized treatment period can last up to approximately 152 weeks. Some participants may continue into a long-term extension lasting up to about 164 weeks, while others will complete the study by around 60 weeks. Throughout the study, participants are monitored regularly for treatment response using measures like the Hidradenitis Suppurativa Clinical Response HiSCR75 up to Week 16. Researchers also assess skin pain, quality of life, and skin lesion changes. Safety is tracked through adverse event reporting and laboratory tests for up to the studys end. Overall participation can last up to 164 weeks depending on extension study involvement.

Age: 18Years +All GendersPhase 2
85 locations
S

Actively Recruiting

Researchers are conducting a combined phase 2b and phase 3 clinical trial to study CSL300 Clazakizumab in adults with end stage kidney disease ESKD who are undergoing maintenance dialysis. The study aims to find the right dose of CSL300 and then evaluate its effects on cardiovascular outcomes and safety in people with systemic inflammation and either atherosclerotic cardiovascular disease ASCVD or diabetes. This multicenter, randomized, double-blind, placebo-controlled trial is designed to provide detailed information on the drugs impact and risks. The study is divided into two parts. Part 1 phase 2b focuses on identifying the optimal dose of CSL300 compared to a placebo over 12 weeks. Part 2 phase 3 assesses the efficacy and safety of CSL300 versus placebo on cardiovascular events such as cardiovascular death or heart attack over approximately 5 years. Participants receive intravenous doses of CSL300 or placebo. The placebo matches the CSL300 product minus the active ingredient. Participants will be monitored through regular assessments including blood tests to measure markers of inflammation like high-sensitivity C-reactive protein hs-CRP, other blood components, and drug levels. The trial tracks cardiovascular events and safety outcomes over the study period. The research team will also observe changes in several blood markers related to inflammation and cardiovascular health. The total follow-up may last up to about five years to fully capture long-term effects and safety.

Age: 18Years +All GendersPhase 2Phase 3
566 locations
P

Actively Recruiting

This research aims to study whether care provided by family members or caregivers can help prevent delirium in patients over 65 years old who undergo surgery for hip fracture. The study is a randomized, single-blind, parallel clinical trial conducted in two hospitals in Spain where patients are admitted to trauma units and accompanied by a family member or caregiver. The trial compares two groups one receiving the Delirium Zero protocol and the other receiving standard care. Participants in the intervention group will experience the Delirium Zero protocol, which includes a patient orientation poster updated daily by the caregiver, a clock placed next to the poster, and a daily checklist that caregivers complete to verify preventive measures taken. Nurses collect these checklists daily until the patient is discharged. The control group receives usual care for delirium prevention, which includes information and guidance provided to patients and families. Both groups are monitored from admission until discharge or up to six weeks. During the study, participants are closely observed for the occurrence, severity, duration, and number of delirium episodes. The research team also assesses how well caregivers follow the Delirium Zero protocol. Evaluations occur from admission until hospital discharge or six weeks, whichever comes first. The total participation time varies depending on the patients hospital stay, with daily assessments by nurses and family involvement in the intervention group.

Age: 65Years +All GendersPhase Not Applicable
2 locations
O

Actively Recruiting

Diffuse large B-cell lymphoma DLBCL is a fast-growing and uncommon cancer affecting certain immune cells, and it is the most common type of non-Hodgkin lymphoma. Follicular lymphoma FL is a slower-growing form of non-Hodgkin lymphoma. This research aims to evaluate how well the investigational drug epcoritamab works in adults with advanced DLBCL and FL in real-world medical settings. Participants will receive epcoritamab as prescribed by their doctors following local country guidelines. The study will include about 700 adults treated across roughly 80 sites in 12 to 20 countries. Treatment is given as subcutaneous injections, and the study observes participants over up to three years to gather effectiveness information. During the study, participants will continue their regular hospital or clinic visits as part of their usual care, without extra procedures or visits added by the trial. Researchers will monitor the percentage of participants who achieve an overall response to the treatment over approximately three years. The study is observational, meaning it follows patients receiving epcoritamab under normal clinical practice without altering their care.

Age: 18Years +All Genders
73 locations

1-10 of 12

1